期刊文献+

术前外周血清蛋白与球蛋白比值在非转移性肾透明细胞癌预后预测中的价值 被引量:2

Value of preoperative peripheral blood albumin-to-globulin ratio in predicting the prognosis of non-metastatic clear cell renal cell carcinoma
原文传递
导出
摘要 目的探讨术前外周血清蛋白与球蛋白比值(AGR)对非转移性肾透明细胞癌(NMCCRCC)患者预后预测中的价值。方法回顾性分析2012年1月至2014年12月大连大学附属中山医院收治的61例术后病理确诊为NMCCRCC患者的临床病理及术后随访资料。根据受试者工作特征曲线(ROC)确定AGR最佳截点值,根据截点值分为高AGR组(AGR≥1.59)和低AGR组(AGR<1.59)。对影响NMCCRCC患者预后的因素进行单因素和多因素分析。结果61例NMCCRCC患者中,高AGR组38例(62.3%),低AGR组23例(37.7%)。两组患者年龄、球蛋白水平、临床分期、复发情况比较,差异均有统计学意义(均P<0.05)。低AGR组的总生存时间、无病生存时间均短于高AGR组,差异均有统计学意义(均P<0.05)。多因素Cox回归分析显示,AGR<1.59是患者总生存及复发的独立影响因素(HR=0.233,95%CI 0.073~0.742,P=0.014;HR=0.343,95%CI 0.134~0.873,P=0.025)。结论术前AGR对NMCCRCC患者预后有预测价值。 Objective To investigate the prognostic value of preoperative peripheral blood albumin-to-globulin ratio(AGR)for patients with non-metastatic clear cell renal cell carcinoma(NMCCRCC).Methods The clinicopathological and postoperative follow-up data of 61 patients with NMCCRCC confirmed by postoperative pathology who were admitted to Zhongshan Hospital of Dalian University from January 2012 to December 2014 was retrospectively analyzed.According to the receiver operating characteristic curve(ROC),the optimal cut-off value of AGR was determined.According to the cut-off value,the patients were divided into high AGR group(AGR≥1.59)and low AGR group(AGR<1.59).The factors affecting the prognosis of NMCCRCC patients were analyzed by using univariate and multivariate analyses.Results Among 61 patients with NMCCRCC,38 cases(62.3%)were in high AGR group and 23 cases(37.7%)were in low AGR group.The differences in age,globulin level,clinical staging,and recurrence status between the two groups were statistically significant(all P<0.05).The overall survival time and disease-free survival time in low AGR group were shorter than those in high AGR group,and the differences were statistically significant(both P<0.05).Multivariate Cox regression analysis showed that AGR<1.59 was the independent influencing factor for overall survival and recurrence(HR=0.233,95%CI 0.073-0.742,P=0.014;HR=0.343,95%CI 0.134-0.873,P=0.025).Conclusion Preoperative AGR is valuable in predicting the prognosis of NMCCRCC patients.
作者 李凯 陈乾 唐怀鼎 彭大帅 付启忠 刘颖 Li Kai;Chen Qian;Tang Huaiding;Peng Dashuai;Fu Qizhong;Liu Ying(Department of Urology,Zhongshan Hospital,Dalian University,Dalian 116001,China)
出处 《肿瘤研究与临床》 CAS 2020年第6期410-414,共5页 Cancer Research and Clinic
基金 大连市医学科学研究计划(1911110)。
关键词 肾肿瘤 清蛋白与球蛋白比值 非转移性肾透明细胞癌 复发 预后 Renal neoplasms Albumin-to-globulin ratio Non-metastatic renal clear cell carcinoma Recurrence Prognosis
  • 相关文献

参考文献1

二级参考文献13

  • 1Obara W, Mizutani Y, Oyama C, et al. Prospective study of combined treatment with interferon alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. Int J Urol, 2008, 15: 794-799.
  • 2Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioe conomic burden of metastatic renal cell carcinoma (mRCC) : a literature review. Cancer Treat Rev, 2008, 34:193-205.
  • 3Taari K, Perttila I, Nisen H. Laparoscopic versus open nephrectomy for renal cell carcinoma? Scand J Surg, 2004, 93:132-136.
  • 4Rubinstein M, Moinzadeh A, Colombo JR Jr. Energy sources for laparoscopic partial nephrectomy critical appraisal. Int Braz J Urol, 2007, 33:3-10.
  • 5Chapman TN, Sharma S, Zhang S. Laparoscopic lymph node dissection in clinically node-negative patients undergoing laparoscopic nephrectomy for renal carcinoma. Urology, 2008, 71:287-291.
  • 6Godoy G, O'Malley RL, Taneja SS. Lymph node dissection during the surgical treatment of renal cancer in the modern era. Int Braz J Urol, 2008, 34: 132-142.
  • 7Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J, 2008, 14: 308-314.
  • 8Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am, 2008, 35: 673-678.
  • 9Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: Final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol, 2009, 55:28-34.
  • 10颜克钧,王林辉,孙颖浩,钱松溪,马永江.偶发性肾癌的诊治体会(附44例报告)[J].中国肿瘤临床与康复,2000,7(2):54-55. 被引量:4

共引文献73

同被引文献10

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部